Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 10/20 | 0.53 |
| ▸ | HTR2C | P28335 | 6/20 | 0.53 |
| ▸ | HTR7 | P34969 | 5/20 | 0.53 |
| ▸ | HTR6 | P50406 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.46 |
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 5/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6523137 | 1.00 | HTR2A (0.53) | HTR2AHTR2CHTR7HTR6MAPT | |
| SCHEMBL6523131 | 1.00 | HTR2A (0.53) | HTR2AHTR2CHTR7HTR6MAPT | |
| SCHEMBL10922949 | 0.95 | HTR2A (0.51) | HTR2AHTR2CHTR7HTR6MAPT | |
| SCHEMBL16561282 | 0.86 | HTR2A (0.51) | HTR2AHTR2CHTR7HTR6MAPT | |
| SCHEMBL12794816 | 0.86 | HTR2A (0.51) | HTR2AHTR2CHTR7HTR6MAPT | |
| SCHEMBL16561283 | 0.86 | HTR2A (0.51) | HTR2AHTR2CHTR7HTR6MAPT | |
| SCHEMBL16561281 | 0.86 | HTR2A (0.51) | HTR2AHTR2CHTR7HTR6MAPT | |
| SCHEMBL22738428 | 0.84 | HTR2A (0.48) | HTR2AHTR2CHTR7HTR6MAPT | |
| Setoperone SCHEMBL122185 | 0.83 | HTR2C (0.64) | HTR2AHTR2CHTR7HTR6MAPT | |
| SCHEMBL22738546 | 0.81 | HTR2A (0.50) | HTR2AHTR2CHTR7HTR6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3106166-B1 | COMPOUNDS FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM THERAPEUTICS LLC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3106166-B1 | COMPOUNDS FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM THERAPEUTICS LLC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-9834555-B2 | Method for treating pain syndrome and other disorders | VM Therapeutics LLC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834555-B2 | Method for treating pain syndrome and other disorders | VM Therapeutics LLC. (US) | 2017-12-05 | — | — | US | disclosed |
| EP-3106166-A1 | COMPOUNDS FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM Therapeutics LLC (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-3106166-A1 | COMPOUNDS FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM Therapeutics LLC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160318930-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM THERAPEUTICS LLC (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318930-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM THERAPEUTICS LLC (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318930-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM THERAPEUTICS LLC (US) | 2016-11-03 | — | — | US | disclosed |
| US-9402848-B2 | Method for treating pain syndrome and other disorders | VM THERAPEUTICS LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-8865727-B2 | Method for treating pain syndrome and other disorders | VM THERAPEUTICS LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-20110053960-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM DISCOVERY INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053960-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM DISCOVERY INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053960-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM DISCOVERY INC. (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2009108798-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | VM DISCOVERY INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| EP-0070053-B1 | NOVEL BICYCLIC PYRIMIDIN-5-ONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-04-16 | — | — | EP | disclosed |
| US-4548938-A | PSYCHOTROPIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-10-22 | — | — | US | disclosed |
| US-4529727-A | Pyrimido[2,1-b][1,3]-thiazines | JANSSEN PHARMACEUTICAL, N.V. (BE) | 1985-07-16 | — | — | US | disclosed |
| US-4443451-A | PSYCHOTROPIC, ANTIHISTAMINES, ANTISEROTONINE | JANSSEN PHARMACEUTICA N.V. (BE) | 1984-04-17 | — | — | US | disclosed |
| EP-0070053-A2 | Novel bicyclic pyrimidin-5-one derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318930-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | CACNA1G, CACNA1H, CACNA1A | HTR2A 606/4885HTR2C 981/4885HTR7 1284/4885 |
| US-20110053960-A1 | METHOD FOR TREATING PAIN SYNDROME AND OTHER DISORDERS | CACNA1G, CACNA1H, CACNA1A | HTR2A 606/4885HTR2C 981/4885HTR7 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.